J H Chung
Overview
Explore the profile of J H Chung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
298
Citations
3343
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cho S, Sun S, Mun J, Kim C, Kim S, Cho S, et al.
Br J Dermatol
. 2019 Aug;
182(6):1388-1394.
PMID: 31449661
Background: Deep convolutional neural networks (DCNNs) can classify skin diseases at a level equivalent to a dermatologist, but their performance in specific areas requires further research. Objective: To evaluate the...
12.
Sokol E, Feng Y, Jin D, Basudan A, Lee A, Atkinson J, et al.
Ann Oncol
. 2018 Nov;
30(1):115-123.
PMID: 30423024
Background: Invasive lobular carcinoma (ILC) as a disease entity distinct from invasive ductal carcinoma (IDC) has merited focused studies of the genomic landscape, but those to date are largely limited...
13.
Lee J, Park H, Yoon H, Chung J, Cho S
J Eur Acad Dermatol Venereol
. 2018 Jun;
32(12):2208-2216.
PMID: 29888507
Background: Fibrosis is thought to be the main pathophysiology of scleroderma, and myofibroblasts play the main role in abnormal fibrotic pathologies. Altered distribution of dermal dendritic cells (DDCs) and vascular...
14.
Park S, Kim H, Kim J, Kim J, Oh Y, Kim S, et al.
Br J Surg
. 2018 Apr;
105(9):1155-1162.
PMID: 29663333
Background: In the eighth edition of the AJCC staging system for differentiated thyroid carcinoma (DTC), minimal extrathyroidal extension (ETE) is no longer a determinant of T3 category. Instead, gross ETE...
15.
Kim H, Kim T, Choe J, Kim J, Kim J, Kim Y, et al.
Br J Surg
. 2018 Feb;
105(3):270-278.
PMID: 29405275
Background: Surgery is the most important treatment modality for papillary thyroid cancer (PTC). However, the relationship between surgeon volume and long-term oncological outcomes has not been explored. Methods: Patients diagnosed...
16.
Hartmaier R, Trabucco S, Priedigkeit N, Chung J, Parachoniak C, Vanden Borre P, et al.
Ann Oncol
. 2018 Jan;
29(4):872-880.
PMID: 29360925
Background: Estrogen receptor-positive (ER-positive) metastatic breast cancer is often intractable due to endocrine therapy resistance. Although ESR1 promoter switching events have been associated with endocrine-therapy resistance, recurrent ESR1 fusion proteins...
17.
Chung J, Pavlick D, Hartmaier R, Schrock A, Young L, Forcier B, et al.
Ann Oncol
. 2017 Sep;
28(11):2866-2873.
PMID: 28945887
Background: Genomic changes that occur in breast cancer during the course of disease have been informed by sequencing of primary and metastatic tumor tissue. For patients with relapsed and metastatic...
18.
Yun J, Woo Y, Kim M, Chung J, Jung M, Park H
Br J Dermatol
. 2017 Sep;
177(3):e72.
PMID: 28940280
No abstract available.
19.
Kim E, Kim Y, Kim S, Kim J, Tian Y, Doh E, et al.
Br J Dermatol
. 2017 Aug;
178(2):492-501.
PMID: 28845522
Background: Adipose tissue is now appreciated as the pivotal regulator of metabolic and endocrine functions. Subcutaneous (SC) fat, in contrast to visceral fat, may protect against metabolic syndrome and systemic...
20.
Lee D, Jee J, Cho Y, Jang J, Yu T, Kim T, et al.
Osteoporos Int
. 2017 Feb;
28(4):1377-1384.
PMID: 28188454
Introduction: There is no consensus on the minimal serum 25-hydroxyvitamin D [25(OH)D] concentration required to maintain bone health. The aim of this study was to investigate the relationship between 25(OH)D...